The global market for VEGF-A Inhibitor was valued at US$ 11150 million in the year 2023 and is projected to reach a revised size of US$ 14570 million by 2030, growing at a CAGR of 3.9% during the forecast period.

VEGF-A Inhibitor Market

VEGF-A (Vascular endothelial growth factor A) inhibitors are a class of drugs used to treat a variety of conditions, especially certain types of cancer and eye diseases such as wet age-related macular degeneration. It acts by inhibiting the biological activity of Vascular Endothelial Growth Factor A (VEGF-A).

North American market for VEGF-A Inhibitor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for VEGF-A Inhibitor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global manufacturers of VEGF-A Inhibitor include Novartis, Roche, Pfizer, Chengdu Kanghong Biotechnologies Co., Ltd., Innovent Biologics, Luye Pharma, 3SBio, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for VEGF-A Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding VEGF-A Inhibitor.

The VEGF-A Inhibitor market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global VEGF-A Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the VEGF-A Inhibitor manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of VEGF-A Inhibitor Market Report

Report Metric	Details
Report Name	VEGF-A Inhibitor Market
Accounted market size in year	US$ 11150 million
Forecasted market size in 2030	US$ 14570 million
CAGR	3.9%
Base Year	year
Forecasted years	2024 - 2030
by Type	Monoclonal Antibody Small Molecule Compound
by Application	Hospital Clinic Others
Production by Region	North America Europe China Japan
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Novartis, Roche, Pfizer, Chengdu Kanghong Biotechnologies Co., Ltd., Innovent Biologics, Luye Pharma, 3SBio
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of VEGF-A Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of VEGF-A Inhibitor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is VEGF-A Inhibitor Market growing?

Ans: The VEGF-A Inhibitor Market witnessing a CAGR of 3.9% during the forecast period 2024-2030.

What is the VEGF-A Inhibitor Market size in 2030?

Ans: The VEGF-A Inhibitor Market size in 2030 will be US$ 14570 million.

Who are the main players in the VEGF-A Inhibitor Market report?

Ans: The main players in the VEGF-A Inhibitor Market are Novartis, Roche, Pfizer, Chengdu Kanghong Biotechnologies Co., Ltd., Innovent Biologics, Luye Pharma, 3SBio

What are the Application segmentation covered in the VEGF-A Inhibitor Market report?

Ans: The Applications covered in the VEGF-A Inhibitor Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the VEGF-A Inhibitor Market report?

Ans: The Types covered in the VEGF-A Inhibitor Market report are Monoclonal Antibody, Small Molecule Compound

1 VEGF-A Inhibitor Market Overview

1.1 Product Definition

1.2 VEGF-A Inhibitor by Type

1.2.1 Global VEGF-A Inhibitor Market Value Comparison by Type (2024-2030)

1.2.2 Monoclonal Antibody

1.2.3 Small Molecule Compound

1.3 VEGF-A Inhibitor by Application

1.3.1 Global VEGF-A Inhibitor Market Value by Application (2024-2030)

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Others

1.4 Global VEGF-A Inhibitor Market Size Estimates and Forecasts

1.4.1 Global VEGF-A Inhibitor Revenue 2019-2030

1.4.2 Global VEGF-A Inhibitor Sales 2019-2030

1.4.3 Global VEGF-A Inhibitor Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 VEGF-A Inhibitor Market Competition by Manufacturers

2.1 Global VEGF-A Inhibitor Sales Market Share by Manufacturers (2019-2024)

2.2 Global VEGF-A Inhibitor Revenue Market Share by Manufacturers (2019-2024)

2.3 Global VEGF-A Inhibitor Average Price by Manufacturers (2019-2024)

2.4 Global Key Players of VEGF-A Inhibitor, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of VEGF-A Inhibitor, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of VEGF-A Inhibitor, Product Type & Application

2.7 Global Key Manufacturers of VEGF-A Inhibitor, Date of Enter into This Industry

2.8 Global VEGF-A Inhibitor Market Competitive Situation and Trends

2.8.1 Global VEGF-A Inhibitor Market Concentration Rate

2.8.2 The Global 5 and 10 Largest VEGF-A Inhibitor Players Market Share by Revenue

2.8.3 Global VEGF-A Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global VEGF-A Inhibitor Market Scenario by Region

3.1 Global VEGF-A Inhibitor Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global VEGF-A Inhibitor Sales by Region: 2019-2030

3.2.1 Global VEGF-A Inhibitor Sales by Region: 2019-2024

3.2.2 Global VEGF-A Inhibitor Sales by Region: 2025-2030

3.3 Global VEGF-A Inhibitor Revenue by Region: 2019-2030

3.3.1 Global VEGF-A Inhibitor Revenue by Region: 2019-2024

3.3.2 Global VEGF-A Inhibitor Revenue by Region: 2025-2030

3.4 North America VEGF-A Inhibitor Market Facts & Figures by Country

3.4.1 North America VEGF-A Inhibitor Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America VEGF-A Inhibitor Sales by Country (2019-2030)

3.4.3 North America VEGF-A Inhibitor Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe VEGF-A Inhibitor Market Facts & Figures by Country

3.5.1 Europe VEGF-A Inhibitor Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe VEGF-A Inhibitor Sales by Country (2019-2030)

3.5.3 Europe VEGF-A Inhibitor Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific VEGF-A Inhibitor Market Facts & Figures by Region

3.6.1 Asia Pacific VEGF-A Inhibitor Market Size by Region: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific VEGF-A Inhibitor Sales by Region (2019-2030)

3.6.3 Asia Pacific VEGF-A Inhibitor Revenue by Region (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America VEGF-A Inhibitor Market Facts & Figures by Country

3.7.1 Latin America VEGF-A Inhibitor Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America VEGF-A Inhibitor Sales by Country (2019-2030)

3.7.3 Latin America VEGF-A Inhibitor Revenue by Country

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa VEGF-A Inhibitor Market Facts & Figures by Country

3.8.1 Middle East and Africa VEGF-A Inhibitor Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa VEGF-A Inhibitor Sales by Country (2019-2030)

3.8.3 Middle East and Africa VEGF-A Inhibitor Revenue by Country

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global VEGF-A Inhibitor Sales by Type (2019-2030)

4.1.1 Global VEGF-A Inhibitor Sales by Type (2019-2024)

4.1.2 Global VEGF-A Inhibitor Sales by Type (2025-2030)

4.1.3 Global VEGF-A Inhibitor Sales Market Share by Type (2019-2030)

4.2 Global VEGF-A Inhibitor Revenue by Type (2019-2030)

4.2.1 Global VEGF-A Inhibitor Revenue by Type (2019-2024)

4.2.2 Global VEGF-A Inhibitor Revenue by Type (2025-2030)

4.2.3 Global VEGF-A Inhibitor Revenue Market Share by Type (2019-2030)

4.3 Global VEGF-A Inhibitor Price by Type (2019-2030)

5 Segment by Application

5.1 Global VEGF-A Inhibitor Sales by Application (2019-2030)

5.1.1 Global VEGF-A Inhibitor Sales by Application (2019-2024)

5.1.2 Global VEGF-A Inhibitor Sales by Application (2025-2030)

5.1.3 Global VEGF-A Inhibitor Sales Market Share by Application (2019-2030)

5.2 Global VEGF-A Inhibitor Revenue by Application (2019-2030)

5.2.1 Global VEGF-A Inhibitor Revenue by Application (2019-2024)

5.2.2 Global VEGF-A Inhibitor Revenue by Application (2025-2030)

5.2.3 Global VEGF-A Inhibitor Revenue Market Share by Application (2019-2030)

5.3 Global VEGF-A Inhibitor Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Novartis

6.1.1 Novartis Company Information

6.1.2 Novartis Description and Business Overview

6.1.3 Novartis VEGF-A Inhibitor Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Novartis VEGF-A Inhibitor Product Portfolio

6.1.5 Novartis Recent Developments/Updates

6.2 Roche

6.2.1 Roche Company Information

6.2.2 Roche Description and Business Overview

6.2.3 Roche VEGF-A Inhibitor Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Roche VEGF-A Inhibitor Product Portfolio

6.2.5 Roche Recent Developments/Updates

6.3 Pfizer

6.3.1 Pfizer Company Information

6.3.2 Pfizer Description and Business Overview

6.3.3 Pfizer VEGF-A Inhibitor Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Pfizer VEGF-A Inhibitor Product Portfolio

6.3.5 Pfizer Recent Developments/Updates

6.4 Chengdu Kanghong Biotechnologies Co., Ltd.

6.4.1 Chengdu Kanghong Biotechnologies Co., Ltd. Company Information

6.4.2 Chengdu Kanghong Biotechnologies Co., Ltd. Description and Business Overview

6.4.3 Chengdu Kanghong Biotechnologies Co., Ltd. VEGF-A Inhibitor Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Chengdu Kanghong Biotechnologies Co., Ltd. VEGF-A Inhibitor Product Portfolio

6.4.5 Chengdu Kanghong Biotechnologies Co., Ltd. Recent Developments/Updates

6.5 Innovent Biologics

6.5.1 Innovent Biologics Company Information

6.5.2 Innovent Biologics Description and Business Overview

6.5.3 Innovent Biologics VEGF-A Inhibitor Sales, Revenue and Gross Margin (2019-2024)

6.5.4 Innovent Biologics VEGF-A Inhibitor Product Portfolio

6.5.5 Innovent Biologics Recent Developments/Updates

6.6 Luye Pharma

6.6.1 Luye Pharma Company Information

6.6.2 Luye Pharma Description and Business Overview

6.6.3 Luye Pharma VEGF-A Inhibitor Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Luye Pharma VEGF-A Inhibitor Product Portfolio

6.6.5 Luye Pharma Recent Developments/Updates

6.7 3SBio

6.7.1 3SBio Company Information

6.7.2 3SBio Description and Business Overview

6.7.3 3SBio VEGF-A Inhibitor Sales, Revenue and Gross Margin (2019-2024)

6.7.4 3SBio VEGF-A Inhibitor Product Portfolio

6.7.5 3SBio Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 VEGF-A Inhibitor Industry Chain Analysis

7.2 VEGF-A Inhibitor Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 VEGF-A Inhibitor Production Mode & Process

7.4 VEGF-A Inhibitor Sales and Marketing

7.4.1 VEGF-A Inhibitor Sales Channels

7.4.2 VEGF-A Inhibitor Distributors

7.5 VEGF-A Inhibitor Customers

8 VEGF-A Inhibitor Market Dynamics

8.1 VEGF-A Inhibitor Industry Trends

8.2 VEGF-A Inhibitor Market Drivers

8.3 VEGF-A Inhibitor Market Challenges

8.4 VEGF-A Inhibitor Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Chengdu Kanghong Biotechnologies Co., Ltd.

List of Tables

Table 1. Global VEGF-A Inhibitor Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global VEGF-A Inhibitor Market Value by Application (2024-2030) & (US$ Million)

Table 3. Global VEGF-A Inhibitor Market Competitive Situation by Manufacturers in 2023

Table 4. Global VEGF-A Inhibitor Sales (K Units) of Key Manufacturers (2019-2024)

Table 5. Global VEGF-A Inhibitor Sales Market Share by Manufacturers (2019-2024)

Table 6. Global VEGF-A Inhibitor Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global VEGF-A Inhibitor Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market VEGF-A Inhibitor Average Price (US$/Unit) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of VEGF-A Inhibitor, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of VEGF-A Inhibitor, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of VEGF-A Inhibitor, Product Type & Application

Table 12. Global Key Manufacturers of VEGF-A Inhibitor, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global VEGF-A Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in VEGF-A Inhibitor as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global VEGF-A Inhibitor Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global VEGF-A Inhibitor Sales by Region (2019-2024) & (K Units)

Table 18. Global VEGF-A Inhibitor Sales Market Share by Region (2019-2024)

Table 19. Global VEGF-A Inhibitor Sales by Region (2025-2030) & (K Units)

Table 20. Global VEGF-A Inhibitor Sales Market Share by Region (2025-2030)

Table 21. Global VEGF-A Inhibitor Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global VEGF-A Inhibitor Revenue Market Share by Region (2019-2024)

Table 23. Global VEGF-A Inhibitor Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global VEGF-A Inhibitor Revenue Market Share by Region (2025-2030)

Table 25. North America VEGF-A Inhibitor Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America VEGF-A Inhibitor Sales by Country (2019-2024) & (K Units)

Table 27. North America VEGF-A Inhibitor Sales by Country (2025-2030) & (K Units)

Table 28. North America VEGF-A Inhibitor Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America VEGF-A Inhibitor Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe VEGF-A Inhibitor Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe VEGF-A Inhibitor Sales by Country (2019-2024) & (K Units)

Table 32. Europe VEGF-A Inhibitor Sales by Country (2025-2030) & (K Units)

Table 33. Europe VEGF-A Inhibitor Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe VEGF-A Inhibitor Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific VEGF-A Inhibitor Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific VEGF-A Inhibitor Sales by Region (2019-2024) & (K Units)

Table 37. Asia Pacific VEGF-A Inhibitor Sales by Region (2025-2030) & (K Units)

Table 38. Asia Pacific VEGF-A Inhibitor Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific VEGF-A Inhibitor Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America VEGF-A Inhibitor Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America VEGF-A Inhibitor Sales by Country (2019-2024) & (K Units)

Table 42. Latin America VEGF-A Inhibitor Sales by Country (2025-2030) & (K Units)

Table 43. Latin America VEGF-A Inhibitor Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America VEGF-A Inhibitor Revenue Market Share by Country (2019-2024)

Table 45. Middle East and Africa VEGF-A Inhibitor Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East and Africa VEGF-A Inhibitor Sales by Country (2019-2024) & (K Units)

Table 47. Middle East and Africa VEGF-A Inhibitor Sales by Country (2025-2030) & (K Units)

Table 48. Middle East and Africa VEGF-A Inhibitor Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East and Africa VEGF-A Inhibitor Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global VEGF-A Inhibitor Sales (K Units) by Type (2019-2024)

Table 51. Global VEGF-A Inhibitor Sales (K Units) by Type (2025-2030)

Table 52. Global VEGF-A Inhibitor Sales Market Share by Type (2019-2024)

Table 53. Global VEGF-A Inhibitor Sales Market Share by Type (2025-2030)

Table 54. Global VEGF-A Inhibitor Revenue (US$ Million) by Type (2019-2024)

Table 55. Global VEGF-A Inhibitor Revenue (US$ Million) by Type (2025-2030)

Table 56. Global VEGF-A Inhibitor Revenue Market Share by Type (2019-2024)

Table 57. Global VEGF-A Inhibitor Revenue Market Share by Type (2025-2030)

Table 58. Global VEGF-A Inhibitor Price (US$/Unit) by Type (2019-2024)

Table 59. Global VEGF-A Inhibitor Price (US$/Unit) by Type (2025-2030)

Table 60. Global VEGF-A Inhibitor Sales (K Units) by Application (2019-2024)

Table 61. Global VEGF-A Inhibitor Sales (K Units) by Application (2025-2030)

Table 62. Global VEGF-A Inhibitor Sales Market Share by Application (2019-2024)

Table 63. Global VEGF-A Inhibitor Sales Market Share by Application (2025-2030)

Table 64. Global VEGF-A Inhibitor Revenue (US$ Million) by Application (2019-2024)

Table 65. Global VEGF-A Inhibitor Revenue (US$ Million) by Application (2025-2030)

Table 66. Global VEGF-A Inhibitor Revenue Market Share by Application (2019-2024)

Table 67. Global VEGF-A Inhibitor Revenue Market Share by Application (2025-2030)

Table 68. Global VEGF-A Inhibitor Price (US$/Unit) by Application (2019-2024)

Table 69. Global VEGF-A Inhibitor Price (US$/Unit) by Application (2025-2030)

Table 70. Novartis Company Information

Table 71. Novartis Description and Business Overview

Table 72. Novartis VEGF-A Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 73. Novartis VEGF-A Inhibitor Product

Table 74. Novartis Recent Developments/Updates

Table 75. Roche Company Information

Table 76. Roche Description and Business Overview

Table 77. Roche VEGF-A Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 78. Roche VEGF-A Inhibitor Product

Table 79. Roche Recent Developments/Updates

Table 80. Pfizer Company Information

Table 81. Pfizer Description and Business Overview

Table 82. Pfizer VEGF-A Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 83. Pfizer VEGF-A Inhibitor Product

Table 84. Pfizer Recent Developments/Updates

Table 85. Chengdu Kanghong Biotechnologies Co., Ltd. Company Information

Table 86. Chengdu Kanghong Biotechnologies Co., Ltd. Description and Business Overview

Table 87. Chengdu Kanghong Biotechnologies Co., Ltd. VEGF-A Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 88. Chengdu Kanghong Biotechnologies Co., Ltd. VEGF-A Inhibitor Product

Table 89. Chengdu Kanghong Biotechnologies Co., Ltd. Recent Developments/Updates

Table 90. Innovent Biologics Company Information

Table 91. Innovent Biologics Description and Business Overview

Table 92. Innovent Biologics VEGF-A Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 93. Innovent Biologics VEGF-A Inhibitor Product

Table 94. Innovent Biologics Recent Developments/Updates

Table 95. Luye Pharma Company Information

Table 96. Luye Pharma Description and Business Overview

Table 97. Luye Pharma VEGF-A Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 98. Luye Pharma VEGF-A Inhibitor Product

Table 99. Luye Pharma Recent Developments/Updates

Table 100. 3SBio Company Information

Table 101. 3SBio Description and Business Overview

Table 102. 3SBio VEGF-A Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 103. 3SBio VEGF-A Inhibitor Product

Table 104. 3SBio Recent Developments/Updates

Table 105. Key Raw Materials Lists

Table 106. Raw Materials Key Suppliers Lists

Table 107. VEGF-A Inhibitor Distributors List

Table 108. VEGF-A Inhibitor Customers List

Table 109. VEGF-A Inhibitor Market Trends

Table 110. VEGF-A Inhibitor Market Drivers

Table 111. VEGF-A Inhibitor Market Challenges

Table 112. VEGF-A Inhibitor Market Restraints

Table 113. Research Programs/Design for This Report

Table 114. Key Data Information from Secondary Sources

Table 115. Key Data Information from Primary Sources

Table 116. Authors List of This Report

List of Figures

Figure 1. Product Picture of VEGF-A Inhibitor

Figure 2. Global VEGF-A Inhibitor Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global VEGF-A Inhibitor Market Share by Type: 2023 & 2030

Figure 4. Monoclonal Antibody Product Picture

Figure 5. Small Molecule Compound Product Picture

Figure 6. Global VEGF-A Inhibitor Market Value by Application (2024-2030) & (US$ Million)

Figure 7. Global VEGF-A Inhibitor Market Share by Application: 2023 & 2030

Figure 8. Hospital

Figure 9. Clinic

Figure 10. Others

Figure 11. Global VEGF-A Inhibitor Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 12. Global VEGF-A Inhibitor Market Size (2019-2030) & (US$ Million)

Figure 13. Global VEGF-A Inhibitor Sales (2019-2030) & (K Units)

Figure 14. Global VEGF-A Inhibitor Average Price (US$/Unit) & (2019-2030)

Figure 15. VEGF-A Inhibitor Report Years Considered

Figure 16. VEGF-A Inhibitor Sales Share by Manufacturers in 2023

Figure 17. Global VEGF-A Inhibitor Revenue Share by Manufacturers in 2023

Figure 18. Global 5 and 10 Largest VEGF-A Inhibitor Players: Market Share by Revenue in VEGF-A Inhibitor in 2023

Figure 19. VEGF-A Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 20. Global VEGF-A Inhibitor Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 21. North America VEGF-A Inhibitor Sales Market Share by Country (2019-2030)

Figure 22. North America VEGF-A Inhibitor Revenue Market Share by Country (2019-2030)

Figure 23. United States VEGF-A Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 24. Canada VEGF-A Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 25. Europe VEGF-A Inhibitor Sales Market Share by Country (2019-2030)

Figure 26. Europe VEGF-A Inhibitor Revenue Market Share by Country (2019-2030)

Figure 27. Germany VEGF-A Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 28. France VEGF-A Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 29. U.K. VEGF-A Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. Italy VEGF-A Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. Russia VEGF-A Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. Asia Pacific VEGF-A Inhibitor Sales Market Share by Region (2019-2030)

Figure 33. Asia Pacific VEGF-A Inhibitor Revenue Market Share by Region (2019-2030)

Figure 34. China VEGF-A Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 35. Japan VEGF-A Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 36. South Korea VEGF-A Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. India VEGF-A Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. Australia VEGF-A Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. China Taiwan VEGF-A Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. Southeast Asia VEGF-A Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. Latin America VEGF-A Inhibitor Sales Market Share by Country (2019-2030)

Figure 42. Mexico VEGF-A Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. Brazil VEGF-A Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Argentina VEGF-A Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Colombia VEGF-A Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 46. Middle East and Africa VEGF-A Inhibitor Sales Market Share by Country (2019-2030)

Figure 47. Middle East and Africa VEGF-A Inhibitor Revenue Market Share by Country (2019-2030)

Figure 48. Turkey VEGF-A Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 49. Saudi Arabia VEGF-A Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 50. UAE VEGF-A Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 51. Global Sales Market Share of VEGF-A Inhibitor by Type (2019-2030)

Figure 52. Global Revenue Market Share of VEGF-A Inhibitor by Type (2019-2030)

Figure 53. Global VEGF-A Inhibitor Price (US$/Unit) by Type (2019-2030)

Figure 54. Global Sales Market Share of VEGF-A Inhibitor by Application (2019-2030)

Figure 55. Global Revenue Market Share of VEGF-A Inhibitor by Application (2019-2030)

Figure 56. Global VEGF-A Inhibitor Price (US$/Unit) by Application (2019-2030)

Figure 57. VEGF-A Inhibitor Value Chain

Figure 58. VEGF-A Inhibitor Production Process

Figure 59. Channels of Distribution (Direct Vs Distribution)

Figure 60. Bottom-up and Top-down Approaches for This Report

Figure 61. Data Triangulation

Figure 62. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions